Michelle Lock joined Relief’s Board of Directors in January 2022 and became Relief’s Interim Chief Executive Officer in November 2023. She has nearly 30 years of biopharmaceutical strategic, operational and commercialization experience. Previously, Michelle served as Chief Operating Officer of Covis Pharma Group, a global specialty pharmaceutical company based in Zug, Switzerland.  Prior to that, she was Senior Vice President and Head of Europe and International at Acceleron Pharma Inc. During her career, Michelle also spent 24 years with Bristol-Myers Squibb. Michelle holds a degree in Science/Nursing at Royal Melbourne University, Australia and studied General Management and Internal General Management at CEDEP, France. She has served as Honorary Ambassador between Switzerland and the US since 2018, as well is a past member of the Board of Directors of the Swiss American Chamber of Commerce and the Interpharma Switzerland Pharmaceutical Industry.